During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with ...

Anthony S. Stein, MD, discusses a study of total marrow and lymphoid irradiation 20 Gy and post-transplant cyclophosphamide in acute myeloid leukemia undergoing allogeneic hematopoietic cell ...

Hany Elmariah, MD, discusses how he sees fedratinib fitting into clincal practice for the treatment of myeloproliferative neoplasms.

Phase 2 data suggest a survival benefit with Bria-IMT and retifanlimab in heavily pretreated HR-positive metastatic breast ...

The DAMO PANDA can accurately detect pancreatic cancer lesions, and FDA breakthrough therapy designation aims to accelerate ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the GRIFFIN and PERSEUS clinical trials of ...

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...

During a a live event, Virginia Kaklamani, MD, DSc, and participants discussed their experiences using a PI3K/AKT inhibitor ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

During a live event, Richard F. Riedel, MD, discussed Desmoid Tumor Working Group and NCCN guidelines for treating patients ...

During a live event, Marc S. Hoffmann, MD, discussed outcomes from the SEQUOIA and ELEVATE-TN studies in chronic lymphocytic ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...